309 related articles for article (PubMed ID: 26033735)
1. TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.
Kaul M; Mark L; Zhang Y; Parhi AK; Lyu YL; Pawlak J; Saravolatz S; Saravolatz LD; Weinstein MP; LaVoie EJ; Pilch DS
Antimicrob Agents Chemother; 2015 Aug; 59(8):4845-55. PubMed ID: 26033735
[TBL] [Abstract][Full Text] [Related]
2. An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo.
Kaul M; Mark L; Zhang Y; Parhi AK; Lavoie EJ; Pilch DS
Antimicrob Agents Chemother; 2013 Dec; 57(12):5860-9. PubMed ID: 24041882
[TBL] [Abstract][Full Text] [Related]
3. Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant
Bryan E; Ferrer-González E; Sagong HY; Fujita J; Mark L; Kaul M; LaVoie EJ; Matsumura H; Pilch DS
ACS Chem Biol; 2023 Mar; 18(3):629-642. PubMed ID: 36854145
[TBL] [Abstract][Full Text] [Related]
4. Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus.
Kaul M; Mark L; Parhi AK; LaVoie EJ; Pilch DS
Antimicrob Agents Chemother; 2016 Jul; 60(7):4290-6. PubMed ID: 27161635
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723.
Kaul M; Mark L; Zhang Y; Parhi AK; LaVoie EJ; Pilch DS
Biochem Pharmacol; 2013 Dec; 86(12):1699-707. PubMed ID: 24148278
[TBL] [Abstract][Full Text] [Related]
6. An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy.
Stokes NR; Baker N; Bennett JM; Berry J; Collins I; Czaplewski LG; Logan A; Macdonald R; Macleod L; Peasley H; Mitchell JP; Nayal N; Yadav A; Srivastava A; Haydon DJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):317-25. PubMed ID: 23114779
[TBL] [Abstract][Full Text] [Related]
7. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics.
Tan CM; Therien AG; Lu J; Lee SH; Caron A; Gill CJ; Lebeau-Jacob C; Benton-Perdomo L; Monteiro JM; Pereira PM; Elsen NL; Wu J; Deschamps K; Petcu M; Wong S; Daigneault E; Kramer S; Liang L; Maxwell E; Claveau D; Vaillancourt J; Skorey K; Tam J; Wang H; Meredith TC; Sillaots S; Wang-Jarantow L; Ramtohul Y; Langlois E; Landry F; Reid JC; Parthasarathy G; Sharma S; Baryshnikova A; Lumb KJ; Pinho MG; Soisson SM; Roemer T
Sci Transl Med; 2012 Mar; 4(126):126ra35. PubMed ID: 22440737
[TBL] [Abstract][Full Text] [Related]
8. β-Lactam Antibiotics with a High Affinity for PBP2 Act Synergistically with the FtsZ-Targeting Agent TXA707 against Methicillin-Resistant Staphylococcus aureus.
Ferrer-González E; Kaul M; Parhi AK; LaVoie EJ; Pilch DS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630190
[TBL] [Abstract][Full Text] [Related]
9. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
10. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
Haydon DJ; Stokes NR; Ure R; Galbraith G; Bennett JM; Brown DR; Baker PJ; Barynin VV; Rice DW; Sedelnikova SE; Heal JR; Sheridan JM; Aiwale ST; Chauhan PK; Srivastava A; Taneja A; Collins I; Errington J; Czaplewski LG
Science; 2008 Sep; 321(5896):1673-5. PubMed ID: 18801997
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RND-type efflux pumps confers the FtsZ-directed prodrug TXY436 with activity against Gram-negative bacteria.
Kaul M; Zhang Y; Parhi AK; Lavoie EJ; Pilch DS
Biochem Pharmacol; 2014 Jun; 89(3):321-8. PubMed ID: 24637241
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
Song D; Bi F; Zhang N; Qin Y; Liu X; Teng Y; Ma S
Bioorg Med Chem; 2020 Nov; 28(21):115729. PubMed ID: 33065440
[TBL] [Abstract][Full Text] [Related]
13. Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.
Luther MK; LaPlante KL
Antimicrob Agents Chemother; 2015 Dec; 59(12):7790-4. PubMed ID: 26369963
[TBL] [Abstract][Full Text] [Related]
14. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
Rio-Marques L; Hartke A; Bizzini A
Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
[TBL] [Abstract][Full Text] [Related]
15. Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
Ni S; Wei H; Li B; Chen F; Liu Y; Chen W; Xu Y; Qiu X; Li X; Lu Y; Liu W; Hu L; Lin D; Wang M; Zheng X; Mao F; Zhu J; Lan L; Li J
J Med Chem; 2017 Oct; 60(19):8145-8159. PubMed ID: 28880552
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
[TBL] [Abstract][Full Text] [Related]
17. Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant
Kaul M; Ferrer-González E; Mark L; Parhi AK; LaVoie EJ; Pilch DS
Med Chem Res; 2022 Oct; 31(10):1705-1715. PubMed ID: 37065467
[TBL] [Abstract][Full Text] [Related]
18. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
19.
Barman TK; Kumar M; Mathur T; Namba E; Singh D; Chaira T; Kurosaka Y; Yamada M; Upadhyay DJ; Masuda N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610202
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
